title: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
abstract: We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL). Three of the 4 patients with unspecified PTCL (PTCLu) achieved complete response (CR); 1 patient relapsed and 1 died of secondary leukemia after consolidation therapy. All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years. The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT). Thus, our regimen appears to be effective for high-risk AILT and SPTCL. However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
authors.affiliation: Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan. tyamaza@med.nihon-u.ac.jp
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Umihiko
authors.initials: U
authors.lastname: Sawada
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kura
authors.forename: Takeyoshi
authors.initials: T
authors.lastname: Ito
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.forename: Shingo
authors.initials: S
authors.lastname: Aikawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takei
authors.forename: Hikaru
authors.initials: H
authors.lastname: Ishizuka
authors.forename: Minoru
authors.initials: M
authors.lastname: Saiki
authors.forename: Kumi
authors.initials: K
authors.lastname: Uenogawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone